

April 4, 2025

## **Sanwa Kagaku Kenkyusho and Nissan Chemical Announce Collaboration to Co-develop SK-2407/SN-001 for DRPLA**

Sanwa Kagaku Kenkyusho Co., Ltd. (Head office : Nagoya city, Aichi Japan, President : Shusaku Isono) and Nissan Chemical Corporation (Head office: Tokyo, Japan, President: Shinsuke Yagi) announced today the agreement to co-develop SK-2407/SN-001, which is a preclinical antisense drug candidate identified through the drug discovery collaboration, for the treatment of dentatorubral-pallidoluyian atrophy (DRPLA) in Japan.

SKK and Nissan Chemical have been working on joint drug discovery research of antisense oligonucleotide for DRPLA since 2019. Under the agreement, Nissan Chemical will manufacture and provide the oligonucleotide active pharmaceutical ingredient, and SKK will conduct the preclinical and clinical studies. The two companies will also seek partners to develop it outside Japan.

DRPLA is a rare progressive neurodegenerative disorder caused by mutations in ATN1 gene with the highest prevalence in the Japanese population. There are high unmet medical needs, but no treatment options are available.

SK-2407/SN-001 is an ATN1-targeting antisense oligonucleotide utilizing Nissan Chemical's proprietary technology featuring novel chemically modified nucleic acid MCE\* with potential for addressing the unmet medical need and providing new therapeutics for DRPLA patients.

\* MCE: 2'-O-[2-(N-Methylcarbamoyl)ethyl]-ribonucleoside

### **About DRPLA**

DRPLA (Dentatorubral-pallidoluysian atrophy) is a type of spinocerebellar degeneration with an autosomal dominant inheritance pattern, a progressive neurological disorder caused by a CAG trinucleotide repeat expansion in the ATN1 gene. The clinical presentations of DRPLA vary with the age of onset that is hastened by the number of CAG repeats. Patients with juvenile-onset (onset < 20 years) DRPLA present with ataxia, myoclonus, epilepsy, and intellectual deterioration, whereas those with adult-onset (onset ≥ 20 years) DRPLA characteristically present with ataxia, choreoathetosis, dementia, and character change. Currently, there is no cure for DRPLA, and the treatment is focused on supportive care and symptom management.

### **About Sanwa Kagaku Kenkyusho Co., Ltd.**

SKK, a subsidiary of Suzuken, is a R&D-based pharmaceutical company by leveraging our capabilities in drug discovery and development, along with open innovation. Our parent company, Suzuken, is one of Japan's leading pharmaceutical wholesalers, with significant strengths in rare disease distribution. To maximize the synergistic efforts, we focus on developing treatments for rare diseases that address "overlooked medical needs."

From drug discovery to manufacturing, and on to sales and distribution, our strength lies in our ability to deliver comprehensive healthcare solutions. Additional information is available at [www.skk-net.com/en/](http://www.skk-net.com/en/).

### **About Nissan Chemical Corporation**

Nissan Chemical Corporation contributes to solving social issues providing products and services through four business areas – Performance materials, Agricultural chemicals, Chemicals, and Healthcare. We will acquire new technologies and accelerate growth in each business area by improving and combining core technologies.

Additional information is available at [www.nissanchem.co.jp/](http://www.nissanchem.co.jp/).

Contact information for inquiries on the above	
Sanwa Kagaku Kenkyusho Co., Ltd. Corporate Strategy Department CSR & Public Relations Group E-mail : info-skk-2@ml.skk-net.com	Nissan Chemical Corporation Corporate Planning Department Planning Office, Public Relations Group E-mail : pr_cpd@nissanchem.co.jp